A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: The ACT NOW study

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages 1855-1862

  Tripathy, Devjit ^a,b   Cobb, Jeff E ^c   Gall, Walter ^c   Adam, Klaus Peter ^c   George, Tabitha ^c   Schwenke, Dawn C ^d,e   Banerji, MaryAnn ^f   Bray, George A ^g   Buchanan, Thomas A ^h   Clement, Stephen C ^k   Henry, Robert R ⁱ   Kitabchi, Abbas E ^j   Mudaliar, Sunder ⁱ   Ratner, Robert E ^l   Stentz, Frankie B ^j   Reaven, Peter D ^d   Musi, Nicolas ^a,b   Ferrannini, Ele ^m   DeFronzo, Ralph A ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c METABOLON INC   (United States)

^d CARL T HAYDEN VA MEDICAL CENTER   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^k INOVA FAIRFAX HOSPITAL   (United States)

^l MEDSTAR RESEARCH INSTITUTE   (United States)

^m INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYBUTYRIC ACID; GLUCOSE; GLYCEROPHOSPHORYLCHOLINE; GLYCOSYLATED HEMOGLOBIN; HYDROXYBUTYRIC ACID; INSULIN; LINOLEOYL GLYCEROPHOSPHOCHOLINE; OLEIC ACID; PIOGLITAZONE; PLACEBO; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MATSUDA INDEX; NORTH AMERICAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; QUANTOSE INDEX; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREDIABETIC STATE; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDIABETIC STATE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84929340495     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3824     Document Type: Article

References (36)

1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
2. DeFronzo RA, Banerji MA, Bray GA, et al. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia. 2010;53:435-445.
3. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49:975-980.
4. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334:299-302.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
6. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
7. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
8. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.
9. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077.
10. Nicholson JK, Wilson ID. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003;2:668-676.
11. Altmaier E, Ramsay SL, Graber A, Mewes HW, Weinberger KM, Suhre K. Bioinformatics analysis of targeted metabolomics-uncovering old and new tales of diabetic mice under medication. Endocrinology. 2008;149:3478-3489.
12. Gall WE, Beebe K, Lawton KA, et al. α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5:e10883.
13. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. 2013;62:1730-1737.
14. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453:396-400.
15. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1:153-161.
16. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010;5:e13953.
17. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311-326.
18. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448-453.
19. Shah SH, Crosslin DR, Haynes CS, et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia. 2012;55:321-330.
20. Cobb J, Gall W, Adam KP, et al. A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol. 2013;7:100-110.
21. Defronzo RA, Banerji M, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009;9:17-25.
22. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981;68:1456-1467.
23. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
24. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. β-Cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) Study. Diabetologia. 2004;47:31-39.
25. Huffman KM, Slentz CA, Bateman LA, et al. Exercise-induced changes in metabolic intermediates, hormones, and inflammatory markers associated with improvements in insulin sensitivity. Diabetes Care. 2011;34:174-176.
26. Cosson E, Hamo-Tchatchouang E, Banu I, et al. A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. Diabetes Metab. 2010;36:312-318.
27. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90:493-500.
28. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55:1430-1435.
29. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-1287.
30. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia. 2001;44:2210-2219.
31. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
32. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:200-206.
33. Gastaldelli A, Casolaro A, Ciociaro D, et al. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2009;297:E225-E230.
34. Bajaj M, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:1916-1923.
35. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52:1364-1370.
36. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292:E871-E883.